NO983876L - Syntetiske HIV-gener - Google Patents

Syntetiske HIV-gener

Info

Publication number
NO983876L
NO983876L NO983876A NO983876A NO983876L NO 983876 L NO983876 L NO 983876L NO 983876 A NO983876 A NO 983876A NO 983876 A NO983876 A NO 983876A NO 983876 L NO983876 L NO 983876L
Authority
NO
Norway
Prior art keywords
hiv genes
synthetic
synthetic hiv
codons
genes
Prior art date
Application number
NO983876A
Other languages
English (en)
Norwegian (no)
Other versions
NO983876D0 (no
Inventor
John W Shiver
Mary-Ellen Davies
Daniel C Freed
Margaret A Liu
Helen C Perry
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO983876D0 publication Critical patent/NO983876D0/no
Publication of NO983876L publication Critical patent/NO983876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO983876A 1996-02-22 1998-08-21 Syntetiske HIV-gener NO983876L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes
PCT/US1997/002294 WO1997031115A2 (en) 1996-02-22 1997-02-18 Synthetic hiv genes

Publications (2)

Publication Number Publication Date
NO983876D0 NO983876D0 (no) 1998-08-21
NO983876L true NO983876L (no) 1998-10-21

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983876A NO983876L (no) 1996-02-22 1998-08-21 Syntetiske HIV-gener

Country Status (27)

Country Link
EP (1) EP0904380B1 (de)
JP (1) JP2000505299A (de)
KR (1) KR19990087126A (de)
CN (1) CN1216064A (de)
AR (1) AR005930A1 (de)
AT (1) ATE309366T1 (de)
AU (1) AU729231B2 (de)
BG (1) BG102784A (de)
BR (1) BR9707672A (de)
CO (1) CO4600706A1 (de)
CZ (1) CZ266798A3 (de)
DE (1) DE69734585T2 (de)
EE (1) EE9800257A (de)
ES (1) ES2251734T3 (de)
HR (1) HRP970092A2 (de)
HU (1) HUP9901112A3 (de)
ID (1) ID16021A (de)
IL (1) IL125547A0 (de)
IS (1) IS4814A (de)
NO (1) NO983876L (de)
NZ (1) NZ331161A (de)
PE (1) PE43298A1 (de)
PL (1) PL328730A1 (de)
SK (1) SK112998A3 (de)
TR (1) TR199801615T2 (de)
WO (1) WO1997031115A2 (de)
YU (1) YU35498A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
CA2258568A1 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
EP2325308A3 (de) 1997-04-04 2011-07-27 The Board of Regents of the University of Nebraska Verfahren und Materialien zur Herstellung und Verwendung transgener Dicamba-abauender Organismen
EP1025244A2 (de) 1997-10-20 2000-08-09 Genzyme Transgenics Corporation Neue modifizierte msp-1 nukleinsäuresequenzen und verfahren zur erhöhung der mrna-niveau und der proteinexpression in zellsystemen
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1433851A3 (de) * 1998-12-31 2004-10-13 Chiron Corporation Verbesserte exprimierung von HIV Polypeptiden und Herstellung von virusähnliche Partikeln
EP1535995A1 (de) * 1998-12-31 2005-06-01 Chiron Corporation Polynukleotide kodierend für Antigene des HIV Type C ENV Polypeptids, und Verwendungen davon
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
WO2001045748A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
EP1411770A4 (de) 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
CA2662511C (en) 2006-10-16 2014-12-30 Monsanto Technology Llc Method for improving plant health by providing dicamba to a dicamba monooxygenase (dmo) transgenic plant or by providing a product of dmo-mediated metabolism to a plant
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219767B (hu) * 1993-01-26 2001-07-30 Leslie R. Coney Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
IL125547A0 (en) 1999-03-12
JP2000505299A (ja) 2000-05-09
ATE309366T1 (de) 2005-11-15
PL328730A1 (en) 1999-02-15
EP0904380A2 (de) 1999-03-31
AR005930A1 (es) 1999-07-21
AU729231B2 (en) 2001-01-25
HUP9901112A3 (en) 2001-06-28
CO4600706A1 (es) 1998-05-08
EE9800257A (et) 1999-02-15
KR19990087126A (ko) 1999-12-15
NO983876D0 (no) 1998-08-21
IS4814A (is) 1998-07-30
ES2251734T3 (es) 2006-05-01
ID16021A (id) 1997-08-28
HRP970092A2 (en) 1998-04-30
DE69734585D1 (de) 2005-12-15
PE43298A1 (es) 1998-08-29
WO1997031115A2 (en) 1997-08-28
NZ331161A (en) 2000-03-27
HUP9901112A2 (hu) 1999-07-28
WO1997031115A3 (en) 1997-10-09
DE69734585T2 (de) 2006-08-10
BG102784A (en) 1999-05-31
CZ266798A3 (cs) 1999-03-17
YU35498A (sh) 1999-07-28
BR9707672A (pt) 1999-04-13
EP0904380B1 (de) 2005-11-09
AU2124697A (en) 1997-09-10
SK112998A3 (en) 2000-04-10
TR199801615T2 (xx) 1998-11-23
CN1216064A (zh) 1999-05-05

Similar Documents

Publication Publication Date Title
NO983876L (no) Syntetiske HIV-gener
DK0969862T3 (da) Syntetisk HIV gag-gener
PT1212358E (pt) Genes sinteticos de papilomavirus humano
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
MXPA03002453A (es) Uso de imidazoquinolinaminas como mejoradores de vacunacion de acido desoxirribonucleico.
NZ505108A (en) Vaccine composition comprising E6 or E7 protein from HPV and CpG oligonucleotide
WO1999061056A3 (en) Methods and products for inducing mucosal immunity
AU1884392A (en) Peptide nucleic acids
NZ333781A (en) Feline vaccine comprising at least three polynucleotide vaccine valencies each comprising a plasmid integrating a gene with one feline pathogen valency
AU2001240109A1 (en) Dna vaccines against poxviruses
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO2001070247A3 (en) Salmonella vaccine materials and methods
NZ338039A (en) Identification of polynucleotides encoding helicobacter polypeptides in the helicobacter genome
WO1999053960A3 (en) Enhancing immune responses to genetic immunization by using a chemokine
EP0647138A4 (de) Polypeptide erhältlich aus fasciola spezien, und vakzine, therapieverfahren und dna sequenzen diese peptide kodierend.
WO2001032697A3 (en) Virulence genes and proteins from brucella melitensis, and their use
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
EA199800750A1 (ru) Синтетические гены вич
EA199900726A1 (ru) Синтетические hiv gag гены
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
AU3628293A (en) Hybrid DNA that codes for a subunit of a bacterial toxin with a hemolysin
WO2002022850A3 (en) Genome arrays utilizing randomly selected nucleic acid fragments
ITVI940084A0 (it) Impilatore per prodotti laminari flessibili, particolarmente per pellied affini.
ES1020613Y (es) Maquina taponadora y acopladora de bozales para botellas, perfeccionada.
EP1640013A3 (de) Inaktivierte Salmonella Impfstoffe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application